1. Efficacy of DC therapy is synergistically enhanced by combination therapy with TAM depletion in mesothelioma mouse models.
Efficacy of DC therapy is synergistically enhanced by combination therapy with TAM depletion in mesothelioma mouse models. A and B, Wild-type, female BALB/c (n = 6/arm) and CBA/J (n = 8/arm) mice were i.p. injected with either 0.5 × 106 AB1 or 20 × 106 AC29 syngeneic tumor cells, respectively. Mice were then treated once on day 10 with either i.p. administration of PBS or mature, autologous tumor lysate loaded DCs. Concurrently, mice were started on control or PLX3397-containing chow until the end of the experiment or until rechallenge. Blood was extracted on t = 15 days and before and after rechallenge in case of CBA/J mice. Animals were monitored daily for the duration of 160 days and euthanized in case of severe illness. C and D, Kaplan–Meier curves of the survival experiments in CBA/J (AC29) and BALB/c (AB1) mesothelioma tumor models. Statistical significance was determined using the log-rank test with P < 0.05 being statistically significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.
Floris Dammeijer et al. Cancer Immunol Res 2017;5:
©2017 by American Association for Cancer Research